Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:NRXP NASDAQ:SPRO NASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$2.79-2.4%$2.86$2.00▼$5.00$11.99M2.1370,132 shs23,466 shsNRXPNRx Pharmaceuticals$3.01-3.2%$2.99$1.10▼$6.01$53.77M1.59420,373 shs190,873 shsSPROSpero Therapeutics$2.47-0.8%$2.19$0.51▼$3.22$139.22M1.331.23 million shs865,146 shsSRZNSurrozen$8.40-0.1%$8.50$5.90▼$18.17$72.05M0.5922,076 shs3,005 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-2.45%-12.54%+10.80%+1.45%-25.45%NRXPNRx Pharmaceuticals-3.22%-10.42%-13.51%+55.96%+20.40%SPROSpero Therapeutics-0.80%-18.75%-13.33%+227.50%+64.67%SRZNSurrozen+0.06%+0.96%-11.95%-13.85%-11.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos1.5343 of 5 stars0.05.00.00.02.51.70.6NRXPNRx Pharmaceuticals2.7621 of 5 stars3.64.00.00.02.20.80.6SPROSpero Therapeutics3.9219 of 5 stars3.33.00.04.72.70.00.6SRZNSurrozen2.772 of 5 stars3.52.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/ANRXPNRx Pharmaceuticals 3.20Buy$28.50846.84% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00102.43% UpsideSRZNSurrozen 3.00Buy$38.50358.33% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, NRXP, SPRO, and SRZN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.006/6/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.005/16/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.005/12/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/30/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/29/2025NRXPNRx PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K584.51N/AN/A$5.51 per share0.51NRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/ASPROSpero Therapeutics$47.98M2.88N/AN/A$0.85 per share2.91SRZNSurrozen$11.64M6.18N/AN/A($6.55) per share-1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$6.45N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)NRXPNRx Pharmaceuticals-$25.13M-$2.01N/AN/AN/AN/AN/A-355.00%8/13/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)SRZNSurrozen-$63.56M-$24.96N/AN/AN/AN/A-842.90%-71.32%8/11/2025 (Estimated)Latest AIMD, NRXP, SPRO, and SRZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025NRXPNRx Pharmaceuticals-$0.31N/AN/AN/AN/AN/A8/11/2025Q2 2025SRZNSurrozen-$1.23N/AN/AN/AN/AN/A8/4/2025Q2 2025SPROSpero Therapeutics-$0.35N/AN/AN/AN/AN/A5/15/2025Q1 2025NRXPNRx Pharmaceuticals-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million5/12/2025Q1 2025AIMDAinosN/A-$1.05N/A-$0.21N/A$0.11 million5/9/2025Q1 2025SRZNSurrozen-$1.09-$3.13-$2.04-$7.43N/A$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.842.001.91NRXPNRx PharmaceuticalsN/A0.220.22SPROSpero TherapeuticsN/A2.562.56SRZNSurrozenN/A10.0210.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ANRXPNRx Pharmaceuticals4.27%SPROSpero Therapeutics25.60%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%NRXPNRx Pharmaceuticals19.00%SPROSpero Therapeutics5.50%SRZNSurrozen45.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.19 million3.76 millionNot OptionableNRXPNRx Pharmaceuticals217.29 million14.00 millionOptionableSPROSpero Therapeutics15055.91 million52.84 millionOptionableSRZNSurrozen808.56 million4.69 millionNot OptionableAIMD, NRXP, SPRO, and SRZN HeadlinesRecent News About These CompaniesSurrozen (NASDAQ:SRZN) Stock Price Down 0.1% - Here's Why4 hours ago | marketbeat.comWe Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business GrowthJuly 1, 2025 | finance.yahoo.comSurrozen (NASDAQ:SRZN) Shares Down 1.4% - What's Next?June 25, 2025 | marketbeat.comDown -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a TurnaroundMay 16, 2025 | zacks.comSurrozen secures patent for tissue repair technologyMay 15, 2025 | investing.comSurrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayMay 14, 2025 | globenewswire.comSurrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 10, 2025 | finanznachrichten.deSurrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comSurrozen files to sell 5.21M shares of common stock for holdersApril 25, 2025 | markets.businessinsider.comSurrozen reports FY24 EPS ($21.67) vs. ($21.33) last yearApril 2, 2025 | markets.businessinsider.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comSurrozen Focuses on Ophthalmology Amid Financial ChallengesApril 1, 2025 | tipranks.comSurrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 31, 2025 | globenewswire.comSurrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 SharesMarch 29, 2025 | insidertrades.comSurrozen to focus Wnt expertise, technologies on ophthalmology programsMarch 27, 2025 | markets.businessinsider.comSurrozen to discontinue development of SZN-043 in alcohol associated hepatitisMarch 26, 2025 | markets.businessinsider.comSurrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 DevelopmentMarch 24, 2025 | quiverquant.comQSurrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye DiseasesMarch 24, 2025 | globenewswire.comSurrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News SummaryJanuary 30, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy RecommendationJanuary 30, 2025 | msn.comH.C. Wainwright sets $32 target on Surrozen stock with Buy ratingJanuary 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeSmart Investors Are Watching These 3 Undervalued StocksBy Gabriel Osorio-Mazilli | July 12, 2025View Smart Investors Are Watching These 3 Undervalued StocksRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherAIMD, NRXP, SPRO, and SRZN Company DescriptionsAinos NASDAQ:AIMD$2.79 -0.07 (-2.45%) As of 07/16/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.NRx Pharmaceuticals NASDAQ:NRXP$3.01 -0.10 (-3.22%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$3.01 0.00 (0.00%) As of 05:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Spero Therapeutics NASDAQ:SPRO$2.47 -0.02 (-0.80%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.51 +0.04 (+1.62%) As of 07:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Surrozen NASDAQ:SRZN$8.40 -0.01 (-0.12%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$8.46 +0.05 (+0.65%) As of 07/16/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
